🚀 VC round data is live in beta, check it out!
Sinopep Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sinopep and similar public comparables like Oscotec, WAVE Life Sciences, Precigen, Corvus Pharma and more.
Sinopep Overview
About Sinopep
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
Founded
2009
HQ
Employees
N/A
Website
Financials (FY)
EV
$2B
Sinopep Financials
Sinopep reported last fiscal year revenue of $238M and EBITDA of $100M.
In the same fiscal year, Sinopep generated $161M in gross profit, $100M in EBITDA, and $59M in net income.
Revenue (LTM)
Sinopep P&L
In the most recent fiscal year, Sinopep reported revenue of $238M and EBITDA of $100M.
Sinopep expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $238M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $161M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 68% | XXX | XXX | XXX |
| EBITDA | — | XXX | $100M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 32% | XXX | XXX | XXX |
| Net Profit | — | XXX | $59M | XXX | XXX | XXX |
| Net Margin | — | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $135M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sinopep Stock Performance
Sinopep has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Sinopep's stock price is $4.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | 0.0% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSinopep Valuation Multiples
Sinopep trades at 6.9x EV/Revenue multiple, and 16.4x EV/EBITDA.
EV / Revenue (LTM)
Sinopep Financial Valuation Multiples
As of April 20, 2026, Sinopep has market cap of $1B and EV of $2B.
Equity research analysts estimate Sinopep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sinopep has a P/E ratio of 23.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 16.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 21.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 10.2x | XXX | XXX | XXX |
| P/E | — | XXX | 23.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (16.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sinopep Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sinopep Margins & Growth Rates
Sinopep's revenue in the last fiscal year grew by 57%.
Sinopep Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 57% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 110% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sinopep Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sinopep | XXX | XXX | XXX | XXX | XXX | XXX |
| Oscotec | XXX | XXX | XXX | XXX | XXX | XXX |
| WAVE Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Precigen | XXX | XXX | XXX | XXX | XXX | XXX |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| SOTHEMA | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinopep M&A Activity
Sinopep acquired XXX companies to date.
Last acquisition by Sinopep was on XXXXXXXX, XXXXX. Sinopep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sinopep
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSinopep Investment Activity
Sinopep invested in XXX companies to date.
Sinopep made its latest investment on XXXXXXXX, XXXXX. Sinopep invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sinopep
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sinopep
| When was Sinopep founded? | Sinopep was founded in 2009. |
| Where is Sinopep headquartered? | Sinopep is headquartered in China. |
| Is Sinopep publicly listed? | Yes, Sinopep is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Sinopep? | Sinopep trades under 688076 ticker. |
| When did Sinopep go public? | Sinopep went public in 2021. |
| Who are competitors of Sinopep? | Sinopep main competitors are Oscotec, WAVE Life Sciences, Precigen, Corvus Pharma. |
| What is the current market cap of Sinopep? | Sinopep's current market cap is $1B. |
| What is the current revenue of Sinopep? | Sinopep's last fiscal year revenue is $238M. |
| What is the current EV/Revenue multiple of Sinopep? | Current revenue multiple of Sinopep is 6.9x. |
| Is Sinopep profitable? | No, Sinopep is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.